Cardio Flashcards
Gold standard for assessing LV mass and volume
Cardiac MRI
Most useful index of LV function
EF
EF =
Stroke volume/EDV
Normal EF
> /=50 %
Biomarkers sensitive for presence of HF
Useful in diagnosis and establishing prognosis and severity
May inc with age, renal impairment and women but falsely low in obese
B type natriuretic peptide
N-terminal pro BNP
Diagnostics for HF (6)
1 laboratory (CBC, electro, BUN, Crea, AST/ALT, UA and/or fasting glucose, OGTT, dyslipidemia, tsh) 2 ECG 3 CXR 4 2D Echo/Doppler 5 BNP, NT Pro BNP 6 Exercise testing
ECG in severe pulmonary hypertension (3)
P pulmonale
R axis deviation
RVH
Best for diagnosing chronic thromboembolic disease
Ventilation/Perfusion scan
Confirms diagnosis of pulmonary hypertension
Cardiac cath
Therap targets in HFpEF (3)
1 control congestion
2 stabilize heart rate and bp
3 improve exercise tolerance
Showed stat significant reduction in hosp but no diff in all cause mortality in HFpEF
Candesartan ARB
ADHF typical HTN Mx
Vasodilators (usually not volume overloaded)
ADHF Typical Normotensive
Diuretics (usually volume overloaded)
ADHF Pulmonary edema with pulmo congestion and hypoxia (4)
Opiates
Vasodilators
Diuretics
O2 non invasive ventilation
ADHF Low output hypoperfusion, with end-organ dysfunction
Vasodilators
Hemodynamic monitoring
Inotropic therapy
ADHF Cardiogenic shock hypotension, low cardiac output, EOF
Inotropic therapy catecholamine
Mech circ support
Interplay of neurohormonal factors with deteriorating function of kidney while therapy is adminstered to preserve the heart
Exacerbated by backward failure, inc intraabd pressure and impairment of venous return
Cardiorenal syndrome
In diabetics with HF, this drug demonstrated dec in CV mortality and hospitalizations for
HF
Empagliflazone SGLT2
induces osmotic diuresis and ketosis
Candidates for ICD prophylactic therapy
NYHA Class II and III
LVEF <35% irrespect of etiology
ICD is appropriate in
Patients with MI
Residual LVEF =30% even asymptomatic
Serious infection from colonization or invasion of heart valves or the mural endocardium by microbe
Infective endocarditis
IE Pathophy
Endothelial injury
Direct infection by virus
Development of platelet fibrin thrombus (bacterial attachment during transient bacteremia)
Organisms enter bloodstream from mucosal surface, skin or site of focal infection
Causes native valve endocarditis
S viridans
Endocarditis in IV drug user
S aureus
Prosthetic valve endocarditis
S epidermidis
Miscellaneous virulent organisms causing IE
Gram neg
Fungi
HACEK
Viridans, strep, staph and HACEK enter via
oral cavity, skin, upper respiratory tract
Streptococcus gallolyticus
Subspecies gallolyticus enter via
GI tract
Enterococci enter via
urinary tract
Endocarditis and Colon CA
strep bovis
The organisms causing IE contain
which adhere to nonbacterial thrombotic endocarditis NBTE sites or
injured epithelium
Microbial surface components recognizing adhesins matrix molecules (MSCRAMMS)
Normal valve
Necrotic, ulcerative, destructive in days
Fever of >/= 39.4
Mx: Surgery
Acute IE
Deformed valve
Insidious, less destructive, weeks to months
Fever of <39.4
Mx: antibiotic
Subacute
Injection drug use associated endocarditis involves the
and is caused by
Occurs among injection drug users
tricuspid valve
s aureus
Polymicrobial endocarditis
Dx of IE is established only
when vegetations are examined histologically and microbiologically
Highly sensitive and specific diagnostic schema
Based on clinical, lab and 2D ECHO
Modified Duke Criteria
Duke Major Criteria
1 Positive blood culture (2 separate)
Viridans, strep gallolyticus, HACEK, staph aureus or CA enterococci in absence of primary focus
Persistently positive
2 Evidence of endocardial involvement
Intracardiac mass on valve or structure in path of regurgitant jet new partial dehiscence of prosthetic valve in 2DECHO
3 New valvular regurgitation (sufficient inc or change in preexisting murmur)
Duke Minor Criteria
1 Predisposition (hx of heart dse or injection drug use)
2 Fever >/= 38
3 Vascular phenomenon: major arterial emboli, septic pulmonary infarct, mycotic aneurysm, ICH, conjunctival hemorrhage, Janeway lesion
4 immunologic phenomenon: glomerulonephritis, Osler’s nodes, Roth spots, rheumatoid factor
5 microbiologic evidence : positive blood culture but not meeting major criterion, sero evidence of active infection wih organism consistent with infective endocarditis
Definite endocarditis is defined by documentation of
Perform for optimal assessment of possible valve endocarditis
Two major criteria
One major and 3 minor criteria
Five minor criteria
Transesophageal echocardiography
Most common clinical manifestation of infective endocarditis
Least
Fever 80-90%
Heart murmur 80-85%
Peripheral: osler, subgungal hemorrhage, janeway
Lab manifestation of IE
Anemia 70-90
Inc ESR 60-99
Inc CRP >90
Circulating immune complex 65-100
Acute endocarditis fever manifestation
Hectically febrile
39.4-40
Subacute endocarditis follows
indolent course
rarely exceeds 39.4
Nephro manifestation of IE
1 immune complex dep on glomerular basement membrane, diffuse hypoconplementic GN, renal dysfunction
2 embolic renal infarct cause flank pain and hematuria rarely causing renal dysfunction
Tender nodes at pulp of digit
Osler nodes
Painless lesions on the palm
Janeway lesion
Nail lesions
Splinter hemorrhage
Retinal hemorrhage with white or pale centers composed of coagulated fibrin in IE
Roth spot
Serologic tests for IE
Brucella, Bartonella, Legionella, Chlamydia
Empirical tx for IE
Acute endocarditis in injection drug user
Vancomycin
Gentamycin
Emipiric
Blood culture negatice subacute NVE
Gentamicin plus
Ampicillin-sulbactan
Ceftriaxone
Empirical
Blood culture negative PVE
Vancomycin
Gentamycin
Cefepime
Rifampin
Tx for Penicillin susceptible strep
Strep gallolyticus
Penicillin G 2-3 mU IV
Ceftriaxone 2g with nonimediate penicillin allergy
Vancomycin for severe or imediate b lactam allergy
all for 4 weeks
Penicillin resistant strep and s gallolyticus Tx
Pen G
Ceftriaxone
Vancomycin
Gentamycin
For 4 weeks
Pen susceptible strep
S gallolyticus Tx
Pen G
Ceftriaxone
Vancomycin
All 4 weeks
Enetrococci IE Tx
Pen G
Ampicillin
Vancomycin
Ampicillin (E faecalis)
For 4-6 weeks
Staph IE Tx
MSSA
Nafcillin Oxacillin Flucloxacillin Cefazolin Vancomycin (only in immediate urticaria and severe penicillin allergy)
MRSA IE Tx
Vancomycin
4-6 w
HACEK IE Tx
Ceftriaxone
Ampi-sul
4 weeks
Coxiella IE Tx
Doxycycline
Hydroxychloroquine
Bartonella IE Tx
Doxycycline
Gentamycin
Stage I HTN AHA JNC
130-139
80-89
Normal BP AHA JNC
<120
<80
Elevated BP AHA JNC
120-129
<80
Stage 2 AHA JNC
>/= 140 >/= 90
Most common cause of secondary hypertension
Obstructive Sleep Apnea 25-50-%
Primary renal disease or
Renovascular disease 25-35% in PLE
Secondary cause of HTN due to
Excess secretion of epinephrine and norepinephrine from tumor of adrenal medulla
Test
Pheochromocytoma
24h urinary fractionated metaneprine/plasma metanephrine
Urinary metabolite: VMA
Other secondary causes of HTN
Cushing’s Dexa supression
Hypothyroidism
Hyperthyroidism
Aortic coarctation -2D ECHO, inc BP UE and low in LE
Primary Hyperparathyroidism - serum Ca
Congenital adrenal hyperplasia - HTN + Hypokalemia with low/N aldosterone and renin, genital ambiguity
Acromegaly - Gh
Drug of choice for acromegaly
ocreotide
45/M BP: 150/90
Initial diagnostic test for primary hypertension
TSH
Others: FBG CBC LP Serum crea with eGFR Na, K, Ca TSH UA ECG
Optional testing for Primary HTN
Echocardiogram
Uric Acid
Urinary albumin to creatinine ratio
Early marker of renal injury
Considered risk factor for renal disease progression and cardiovascular disease
Urinary albumin/creatinine ratio
Macroalbuminemia
Random urine albumin/crea ratio
> 300mg/g
Classic symptom of PAD
Intermittent claudication
Diagnostic of PAD
ABI <0.90
Compares BP in arm and ankle
ABI =
Ankle systolic pressure/Brachial systolic pressure
Interprration of ABI
Normal
0.91 - 1.29
Mild to moderate peripheral arterial
ABI
0.41-0.90
Severe peripheral arterial disease
ABI
<0.41
IgA nephropathy
Berger’s
Nonpharmacologic intervention with highest BP lowering effect among hypertensive patients
DASH diet
-11mmHg
more specific
Dietary approaches to stop hypertension
Eat more fruits and veg, low fat dairy food
Avoid saturated fat and trans
Eat more whole grain, fish, poultry
Limit Na 1500mg/day, sweet, sugary drink and red meat
BP GOAL in patient with co morbidities
<130/80
Thiazide diuretics
WOF
Hyperuricemia
Hyponatremia
Hypokalemia
Contraindicated if given both
ACEi + ARB
Risk for hyperkalemia
Avoid in pregnant
May cause ARF in severe bilateral RAS
ACEi / ARB
do not use in HFrEF
CCB nondihydro/dihydro
Mixing CCB nondihydro with BB will
inc bradycardia and heartblock
First line preferred for symptomatic HF
Loop
furosemide
Preferred for Primary aldosteronism and resistent hypertension
Eplerenone Spironolactone (gynecomastia)
Aldosterone antagonist
Avoid in reactive airway disease
Propranolol
Nadolol
BB noncardioselective
Preferred in HFrEF
Bisoprolol
Metoprolol succinate
Hypertensive crisis
SBP >180
DBP > 120
Surface perechiae
Flea bitten appearance
Onion skin lesion of arteriole
Fibrinoid necrosis of arteriole
Malignant hypertension
Metabolic syndrome
3 out of 5: Central obesity 102 cm M, 88 cm F Hyper TAG >150 mg/dl Low HDL <40 M and <50 F BP of >/= 130/85 FBS of >100 mg/dl